AVH charting perspective, page-46

Transcript from the video :

4. Avita Medical (ASX:AVH)Roger Montgomery (Buy): Avita Medical. Avita produces a product called recell, which is a superior alternative to skin grafting for burns victims. We've just commissioned a survey of U.S. reconstructive and burn surgeons. And what we found was 96% of those who had used the recell product in the last 12 months planned on continuing to doing so. And more importantly, 75% of those surveyed actually said that they'd be interested in using that product in another setting, for example, paediatric and trauma.So we already think the price is reflecting some of the growth that's being anticipated, but we think there's a lot more growth to come because the market is expanding as well as penetration within the existing market. So if it was cheaper, I'd be putting it on a strong buy. But for us it's a buy.

Jessica Amir: And speaking about penetration, they definitely penetrated the ASX last year and for the decade, a market darling. James, what have you got for us?